Evotec SE stock (DE0005664809): Drug discovery leader eyes US biotech partnerships
Published on 05/14/2026 at 16:32 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Evotec SE shares traded at approximately 8.50 EUR on Xetra on May 13, 2026, showing stability in a volatile biotech sector, ad-hoc-news.de as of May 13, 2026. The company continues to deepen partnerships with US pharmaceutical giants, positioning it as a vital player for American investors interested in outsourced drug development.
As of: 14.05.2026
By the editorial team – specialized in equity coverage.
At a glance
- Name: Evotec SE
- Sector/industry: Biotechnology / Drug Discovery
- Headquarters/country: Hamburg, Germany
- Core markets: US, Europe
- Key revenue drivers: Partnerships, milestones, royalties
- Home exchange/listing venue: Xetra (EVT)
- Trading currency: EUR
Official source
For first-hand information on Evotec SE, visit the company’s official website.
Go to the official websiteEvotec SE: core business model
Evotec SE operates an integrated drug discovery and development platform, partnering with pharmaceutical and biotech companies to advance novel therapies from target identification through clinical stages. Headquartered in Hamburg, the firm employs over 5,000 scientists across sites in Europe and the US, leveraging high-throughput screening, AI-driven chemistry, and translational research, ad-hoc-news.de as of May 13, 2026. This model allows clients to access specialized expertise without building internal capabilities.
Main revenue and product drivers for Evotec SE
Evotec SE generates revenue primarily through research partnerships, milestone payments, and royalties from successful drug developments. Key drivers include collaborations with major pharma firms in oncology, neurology, and metabolic diseases, with a growing emphasis on US markets where demand for innovative therapies is high. The company's platform supports end-to-end development, from early discovery to preclinical testing.
Why Evotec SE matters for US investors
Evotec SE's extensive partnerships with US-based pharmaceutical giants provide indirect exposure to the world's largest pharma market for US investors. Listed on Xetra but with significant US operations, the company benefits from American R&D spending trends, making it relevant for portfolios tracking biotech outsourcing amid rising drug development costs.
Read more
Additional news and developments on the stock can be explored via the linked overview pages.
Conclusion
Evotec SE maintains its position as a leader in drug discovery outsourcing, with stable trading and ongoing US partnerships underscoring its strategic importance. Investors monitoring biotech innovation will note the company's robust platform and market exposure. Developments in collaborations remain key to watch.
Disclaimer: This article does not constitute investment advice. Stocks are volatile financial instruments.
Disclaimer regarding our articles: No investment advice, no buy or sell recommendation. Information on prices, companies, and markets is provided without guarantee; changes are possible at any time. Stock market transactions can lead to substantial losses. Our articles are created and reviewed in whole or in part automatically with the support of AI.
